Adjuvant trastuzumab for breast cancer: uncertainties in clinical and economic evidence following early stopping of the HERA trial
- PMID: 21504237
- DOI: 10.2165/11588350-000000000-00000
Adjuvant trastuzumab for breast cancer: uncertainties in clinical and economic evidence following early stopping of the HERA trial
Similar articles
-
The cost-effectiveness issue of adjuvant trastuzumab in early breast cancer.Expert Opin Pharmacother. 2006 Aug;7(12):1617-25. doi: 10.1517/14656566.7.12.1617. Expert Opin Pharmacother. 2006. PMID: 16872264
-
Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab?J Clin Oncol. 2007 Feb 20;25(6):611-3. doi: 10.1200/JCO.2006.09.3542. J Clin Oncol. 2007. PMID: 17308264 No abstract available.
-
An economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancer.Value Health. 2009 Nov-Dec;12 Suppl 3:S82-4. doi: 10.1111/j.1524-4733.2009.00634.x. Value Health. 2009. PMID: 20586989
-
How much will Herceptin really cost?BMJ. 2006 Nov 25;333(7578):1118-20. doi: 10.1136/bmj.39008.624051.BE. BMJ. 2006. PMID: 17124225 Free PMC article. Review.
-
Trastuzumab: a pharmacoeconomic review of its use in early breast cancer.Pharmacoeconomics. 2008;26(8):699-719. doi: 10.2165/00019053-200826080-00006. Pharmacoeconomics. 2008. PMID: 18620462 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical